| Primary |
| Mycobacterium Avium Complex Infection |
54.5% |
| Tuberculosis |
13.6% |
| Hiv Infection |
4.9% |
| Infection |
4.1% |
| Prophylaxis |
3.5% |
| Gastritis Prophylaxis |
2.4% |
| Mycobacterial Infection |
1.9% |
| Pain |
1.9% |
| Atypical Mycobacterial Infection |
1.6% |
| Disseminated Tuberculosis |
1.6% |
| Pulmonary Tuberculosis |
1.6% |
| Insomnia |
1.4% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
| Helicobacter Gastritis |
1.1% |
| Pneumonia |
1.1% |
| Arthralgia |
0.8% |
| Diarrhoea |
0.8% |
| Right Ventricular Failure |
0.8% |
| Atypical Mycobacterial Lymphadenitis |
0.5% |
| Hiv Test |
0.5% |
|
| Pneumonia |
10.5% |
| Death |
7.9% |
| Decreased Appetite |
7.9% |
| Pyrexia |
7.9% |
| White Blood Cell Count Decreased |
7.9% |
| Liver Disorder |
6.6% |
| Hepatic Function Abnormal |
5.3% |
| Meningitis Bacterial |
5.3% |
| Respiratory Failure |
5.3% |
| Rhabdomyolysis |
5.3% |
| Cardiogenic Shock |
3.9% |
| Hypertension |
3.9% |
| Platelet Count Decreased |
3.9% |
| Acute Generalised Exanthematous Pustulosis |
2.6% |
| Asphyxia |
2.6% |
| Bone Marrow Failure |
2.6% |
| Cholestasis |
2.6% |
| Gastroenteritis |
2.6% |
| Hyponatraemia |
2.6% |
| Interstitial Lung Disease |
2.6% |
|
| Secondary |
| Mycobacterium Avium Complex Infection |
34.3% |
| Product Used For Unknown Indication |
14.7% |
| Hiv Infection |
13.1% |
| Drug Use For Unknown Indication |
5.1% |
| Tuberculosis |
4.6% |
| Atypical Mycobacterial Infection |
3.8% |
| Disseminated Tuberculosis |
2.5% |
| Pneumonia Bacterial |
2.3% |
| Antibiotic Therapy |
2.2% |
| Infection |
2.1% |
| Prophylaxis |
2.0% |
| Immunosuppressant Drug Therapy |
1.8% |
| Pain |
1.8% |
| Maternal Exposure During Pregnancy |
1.7% |
| Mycobacterial Infection |
1.7% |
| Pulmonary Tuberculosis |
1.7% |
| Bronchopulmonary Aspergillosis |
1.5% |
| Lentivirus Test Positive |
1.3% |
| Bovine Tuberculosis |
1.0% |
| Arthralgia |
0.9% |
|
| Uveitis |
25.2% |
| Gastroenteritis |
5.6% |
| Intestinal Obstruction |
5.6% |
| Liver Disorder |
5.6% |
| Weight Decreased |
5.6% |
| Platelet Count Decreased |
4.7% |
| Visual Field Defect |
4.7% |
| White Blood Cell Count Decreased |
4.7% |
| Diarrhoea |
3.7% |
| Neutropenia |
3.7% |
| Ototoxicity |
3.7% |
| Renal Tubular Necrosis |
3.7% |
| Thrombocytopenia |
3.7% |
| Cardiogenic Shock |
2.8% |
| Pneumonia |
2.8% |
| Pyrexia |
2.8% |
| Skin Exfoliation |
2.8% |
| Visual Acuity Reduced |
2.8% |
| Vitreous Detachment |
2.8% |
| Vomiting |
2.8% |
|
| Concomitant |
| Hiv Infection |
31.1% |
| Product Used For Unknown Indication |
14.5% |
| Drug Use For Unknown Indication |
13.8% |
| Mycobacterium Avium Complex Infection |
10.1% |
| Tuberculosis |
5.9% |
| Pneumocystis Jiroveci Pneumonia |
3.0% |
| Antifungal Prophylaxis |
2.7% |
| Prophylaxis |
2.5% |
| Antibiotic Prophylaxis |
2.2% |
| Pulmonary Tuberculosis |
2.1% |
| Atypical Mycobacterial Infection |
1.8% |
| Cytomegalovirus Infection |
1.6% |
| Hypertension |
1.5% |
| Chronic Lymphocytic Leukaemia |
1.5% |
| Disseminated Tuberculosis |
1.4% |
| Acquired Immunodeficiency Syndrome |
1.3% |
| Cytomegalovirus Oesophagitis |
0.9% |
| Mycobacterial Infection |
0.8% |
| Atypical Mycobacterial Lymphadenitis |
0.7% |
| Lymph Node Tuberculosis |
0.7% |
|
| Vomiting |
28.0% |
| Renal Failure |
11.2% |
| Renal Failure Acute |
6.4% |
| Respiratory Syncytial Virus Infection |
4.8% |
| Mycobacterium Avium Complex Infection |
4.0% |
| Progressive Multifocal Leukoencephalopathy |
4.0% |
| Tuberculosis |
4.0% |
| Urinary Incontinence |
4.0% |
| Colitis |
3.2% |
| Cytomegalovirus Chorioretinitis |
3.2% |
| Death |
3.2% |
| Hodgkin's Disease |
3.2% |
| Sepsis |
3.2% |
| Visual Field Defect |
3.2% |
| Aids Encephalopathy |
2.4% |
| Cytomegalovirus Viraemia |
2.4% |
| Drug Interaction |
2.4% |
| Dyspnoea |
2.4% |
| Febrile Neutropenia |
2.4% |
| Immune Reconstitution Syndrome |
2.4% |
|
| Interacting |
| Product Used For Unknown Indication |
35.9% |
| Mycobacterium Avium Complex Infection |
16.7% |
| Mycobacterial Infection |
5.1% |
| Immunosuppressant Drug Therapy |
4.5% |
| Bronchopulmonary Aspergillosis |
4.0% |
| Atypical Mycobacterial Infection |
3.0% |
| Bronchiectasis |
3.0% |
| Pulmonary Sarcoidosis |
3.0% |
| Tuberculosis |
3.0% |
| Acquired Immunodeficiency Syndrome |
2.5% |
| Cytomegalovirus Chorioretinitis |
2.5% |
| Oropharyngeal Candidiasis |
2.5% |
| Pulmonary Tuberculosis |
2.5% |
| Disseminated Tuberculosis |
2.0% |
| Immunosuppression |
2.0% |
| Atypical Mycobacterial Lymphadenitis |
1.5% |
| Drug Level Below Therapeutic |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Latent Tuberculosis |
1.5% |
| Pneumonia |
1.5% |
|
| Uveitis |
39.3% |
| Oedema Peripheral |
10.7% |
| Thrombocytopenia |
10.7% |
| Iron Deficiency Anaemia |
7.1% |
| Toxicity To Various Agents |
7.1% |
| Drug Interaction |
3.6% |
| Pneumonia |
3.6% |
| Renal Failure Acute |
3.6% |
| Transplant Rejection |
3.6% |
| Urinary Incontinence |
3.6% |
| Visual Acuity Reduced |
3.6% |
| White Blood Cell Count Decreased |
3.6% |
|
